On June 20, the US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer. 

For more information read the FDA announcement and the Pfizer announcement.

Posted 6/21/2023